Dr. Kelly Posner Gerstenhaber says it's especially important for parents, teachers, coaches and friends to ask survivors direct questions about suicidal thoughts.
Columbia Psychiatrists suggest that researchers, pharmaceutical companies, and the FDA reconsider placebo-controlled, relapse prevention studies in schizophrenia.
"This treatment brings in the parents, finally, and focuses on the ways parents need [to stop] taking over, to break the cycle of anxiety in kids," said Dr. Anne Marie Albano.
“There seems to be a general liability factor, which is genetically transmitted, to having a variety of different psychiatric and neurological disorders,” says Dr. Alan Brown.
Dr. Randy Auerbach spoke with BBC World Service about a clinical trial in which his team of researchers are monitoring adolescents at risk of suicide through their smartphones (forward to 43:26).
Go Medical, in collaboration with Columbia University and the New York State Psychiatric Institute, initiated the evaluation of the safety and pharmacokinetics of the OLANI for opioid use disorder.
Dr. Jeffrey Lieberman and colleagues conclude that the time has come to cease the use of placebo in relapse prevention studies and encourage the use of active comparators.
